Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor Immunotherapy
Authors:
- 1 September 2022
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 8 (9) , 1352-1353
Abstract
This cohort study analyzed the safety and efficacy of immune checkpoint inhibitors in patients with cancer and autoimmune disease, and examined whether immune-related toxic effects were associated with outcomes.Keywords
This publication has 7 references indexed in Scilit:
- Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune DisordersFrontiers in Medicine, 2020
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or PlaceboJAMA Oncology, 2020
- Arthritis & Rheumatology: Vol 71, No 12Arthritis & Rheumatology, 2019
- Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort StudyArthritis & Rheumatology, 2019
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabAnnals of Oncology, 2016
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009